To identify the molecular determinants for attenuation of wild-type Japanese encephalitis (JE) virus strain SA14, the RNA genome of wild-type strain SA14 and its attenuated vaccine virus SA14-2-8 were reverse transcribed, amplified by PCR and sequenced. Comparison of the nucleotide sequence of SA14-2-8 vaccine virus with virulent parent SA14 virus and with two other attenuated vaccine viruses derived from SA14 virus (SA14-14-2/PHK and SA14-14-2/PDK) revealed only seven amino acids in the virulent parent SA14 had been substituted in all three attenuated vaccines. Four were in the envelope (E) protein (E-138, E-176, E-315 and E-439), one in non-structural protein 2B (NS2B-63), one in NS3 (NS3-105), and one in NS4B (NS4B-106). The substitutions at E-315 and E-439 arose due to correction of the SA14/CDC sequence published previously by Nitayaphan et al. (Virology 177, 541-552, 1990). The mutations in NS2B and NS3 are in functional domains of the trypsin-like serine protease. Attenuation of SA14 virus may therefore, in part, be due to alterations in viral protease activity, which could affect replication of the virus.
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Japanese encephalitis (JE) is the most common epidemic viral encephalitis in the world today (Gunakasem et al., 1981) . There are approximately 50 000 clinical cases of JE each year; 25 % are fatal (Huang, 1982; Monath, 1990) . JE virus, like other flaviviruses, has a positive-sense ssRNA genome approximately 11 kb in length, which encodes three structural proteins [core (C), membrane (M) and envelope (E)] and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5; Brinton, 1986) .
The most promising live attenuated JE virus vaccine to control JE is the Chinese SA14-14-2 virus derived from the wild-type strain SA14 (Yu et al., 1973) . The safety and efficacy of this attenuated vaccine have been confirmed in human vaccinees (Ao et al., 1983; Yu et al., 1981 Yu et al., , 1988 . Passage histories of the SA14 attenuated vaccine viruses have been described previously (Ni et The nucleotide sequence data reported here have been deposited with GenBank and assigned the accession numbers U15763 (SA14-2-8) and U14163 (SA14/USA). 1994). Briefly, the first attenuated variant, 12-1-7, was obtained after 100 passages of SA14 in primary hamster kidney (PHK) cells. Vaccine virus SA14-2-8 was derived following treatment of the 12-1-7 virus with ultraviolet irradiation and plaque purification in PHK cells, while vaccine virus SA14-5-3 was derived from 12-1-7 virus by additional plaque purification passages in PHK cells. SA14-14-2/PHK virus was derived by passage of SA14-5-3 virus in suckling mice and plaque purification in PHK cells. SA14-14-2/PDK virus was derived by nine passages of SA 14-14-2/PHK virus in primary dog kidney (PDK) cells.
The molecular basis of JE virus attenuation has not been elucidated, although the entire genomes of both virulent parent SA14 and attenuated vaccine clones, SA14-14-2/PHK (Aihara et al., 1991) and SA14-14-2/ PDK (Nitayaphan et al., 1990) , have been sequenced and compared. Nucleotide sequences of SA14 published by the two groups are not identical, and nucleotide differences were identified throughout the genome between parent and the two attenuated viruses. Aihara et al. (1991) identified 57 nucleotide changes coding for 24 amino acid substitutions between SA14 (which we term SA14/JAP) and SA14-14-2/PHK. Nitayaphan et al. (1990) reported 45 nucleotide changes coding for 15 amino acid substitutions between SA14 (which we term SA14/CDC) and SA14-14-2/PDK viruses. To help to identify the molecular determinants of attenuation of JE virus strain SA14, we determined the nucleotide sequence of the 5' non-coding region and structural protein genes of attenuated vaccine viruses SA14-5-3 and SA14-2-8. The same region of the parental SA14 virus (which we termed SA14/USA) was also cloned and sequenced (Ni et al., 1994) . We now report a comparison of the entire genomes of the SA14-2-8 vaccine virus and the parental virus SA14/USA and identify mutations in the viral serine protease.
The RNA genomes of SA14/USA and SA14-2-8 viruses were reverse transcribed and the resulting cDNA amplified, cloned and sequenced as described by Ni et al. (1994) . The oligonucleotide primers were synthesized based on published SA14 genomic sequence data (Nitayaphan et al., 1990) . Nucleotide changes in SA14/ USA and SA14-2-8 viruses were confirmed by sequencing different PCR products of the same region. Nucleotides 1863-2463 of SA14/CDC virus were sequenced again. A summary of the nucleotide and amino acid differences of the entire genome between the three vaccine viruses (SA14-2-8, SA14-14-2/PHK and SA14-14-2/PDK) and three sequences of SA14 virus (SA14/JAP, SA14/CDC and SA14/USA) are presented in Table 1 . In comparison to the parent SA14 virus, the genome of SA14-2-8 virus had fewer nucleotide and amino acid differences than did SA14-14-2/PHK and SA14-14-2/PDK viruses. This was probably due to different passage histories and fewer passages of SA14 virus to derive the SA14-2-8 virus compared to SA14-14-2 viruses (see Ni et al., 1994) . Amino acid differences in the coding region and nucleotide differences in the 5' and 3' non-coding regions of SA14 virus and its attenuated vaccine viruses are shown in Table 2 .
NS protein genes of the three wild-type SA14 viruses with different passage histories differed by 29 nucleotides encoding 11 substituted amino acids (Tables 1 and 2 ). These differences may reflect the passage histories of the different SA14 viruses (Ni et al., 1994) . The SA14/USA JE virus seed was a mouse brain preparation of SA14 virus while the SA 14/CDC JE virus was derived from the same mouse brain preparation containing SA14/USA virus following three passages in PDK cell culture (Eckels et al., 1988; Nitayaphan et al., 1990) . The SA14/JAP virus was derived by plaque purification of SA14 virus in BHK-21 cells (Aihara et al., 1991) . Table 2 ). Amino acid changes at NS2B-102 and NS4A-49 of SA14/USA are unique changes compared to the SA14 vaccine viruses and other wild-type JE viruses (Table 2) .
Three common amino acids have been substituted in the NS protein genes of the three JE attenuated vaccine viruses derived from the parent SA14 virus, at positions NS2B-63, NS3-105 and NS4B-106 (Table 2 ). In SA14-14-2/PHK and SA14-14-2/PDK viruses, the glutamic acid found at position NS2B-63 in SA14 viruses was substituted by asparagine, while in the SA14-2-8 virus it was replaced by glycine. The NS3-105 substitution was present in all of the vaccine viruses where alanine in the parental SA14 viruses was substituted for a glycine in the three vaccine strains. The isoleucine at position NS4B-106 of the SA14 viruses was substituted by valine in all vaccine viruses. Furthermore, amino acids at positions NS2B-63, NS3-105 and NS4B-106 in all three of the vaccine viruses were different from those of other published wild-type viruses ( Table 2) .
Analysis of the E protein gene of wild-type and vaccine viruses showed that the SA14/CDC sequence, reported by Nitayaphan et al. (1990) , was the same as the vaccine strains at E-315 and E-439 (Ni et al., 1994) . To verify this observation, cDNA to this region of the SA14/CDC virus genome was prepared by RT-PCR and sequenced. This revealed that, contrary to the sequence published by Nitayaphan et al. (1990) , the two amino acids at positions present in the analogous position of nine other mosquitoborne flaviviruses. Chambers et al. (1993) , working with yellow fever virus, and Falgout et al. (1993) , working with dengue 4 virus, found that mutations in this region of NS2B protein reduces or eliminates cleavage efficiency of the virus-encoded serine protease. This suggests that the conserved 'central region' of NS2B has a critical role in the function of the protease. The protease domain in the N-terminal region of the NS3 protein (Chambers et al., 1990a, b) of different flaviviruses contains many conserved amino acids (Fig. 1) . Wild-type JE and tick-borne encephalitis complex viruses have alanine at NS3-105, while the other mosquito-borne flaviviruses contain asparagine; the JE vaccine viruses have glycine at this position. Since the catalytic triad (NS3-51, NS3-75 and NS3-135; Fig. 1 ) of the NS3 serine proteinase has not been mutated, its function will not have been eliminated by the change at NS3-105; however, activity of the enzyme could be affected through alteration of the structure of NS3. This proposal is supported by the observation that substitution in the NS3 protein at amino acid position 105 arose because of a double nucleotide change, suggesting that this substitution was selected during the attenuation process. Taken together these data suggest that protease activity may be altered by changes in conformation and/or structure of the NS2B/NS3 complex, which may contribute to attenuation of JE virus.
Alignment of amino acids in NS4B for different flaviviruses shows that amino acid NS4B-106 is valine for all mosquito-transmitted flaviviruses (including JE vaccine viruses) except yellow fever and the wild-type JE viruses, which contain isoleucine. The significance of the valine amino acid substitution in the attenuated phenotype is questionable since valine at this position is strongly conserved among the JE serocomplex viruses.
We have compared the three sequences of the SA14 virus with the sequences of other wild-type JE virus strains and the three attenuated vaccine strains in an attempt to identify substitutions in the SA14 genome associated with attenuation. Since the SA14 vaccine virus strains have received different passages following the isolation of the attenuated clone 12-1-7 virus (Chen & Wang, 1974; Yu et al., 1981; Li, 1986; Eckels et al., 1988) , nucleotide and amino acid changes unrelated to attenuation may have resulted. Therefore, a comparison of common nucleotide and/or amino acid differences between SA 14 virus and three vaccine derivatives enables the identification of common substitutions that may be responsible for the virus attenuation. Only seven common amino acids were substituted in all three attenuated vaccine viruses compared with parental sequences: four located in the E protein gene at positions E-138, E-176, E-315 and E-439, one at position NS2B-63, another at position NS3-105 and one at position NS4B-106 (Table  2) . From these studies we were unable to identify the precise mutations involved in attenuation of neurovirulence of wild-type strain SA14. However, one or more of the seven common amino acid changes may contribute to attenuation of neurovirulence of wild-type strain SA14. Determining whether or not these common amino acid substitutions in the E protein and serine protease complex are directly involved in attenuation of the vaccine viruses will require an analysis of pathogenesis using recombinant viruses.
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